Stocks & Investing
Stocks and Investing
Stocks and Investing
Wed, May 31, 2023
[ Wed, May 31st 2023
] - WOPRAI
[ Wed, May 31st 2023
] - WOPRAI
[ Wed, May 31st 2023
] - WOPRAI
[ Wed, May 31st 2023
] - WOPRAI
[ Wed, May 31st 2023
] - WOPRAI
[ Wed, May 31st 2023
] - WOPRAI
[ Wed, May 31st 2023
] - WOPRAI
[ Wed, May 31st 2023
] - WOPRAI
[ Wed, May 31st 2023
] - WOPRAI
[ Wed, May 31st 2023
] - WOPRAI
[ Wed, May 31st 2023
] - WOPRAI
[ Wed, May 31st 2023
] - WOPRAI
[ Wed, May 31st 2023
] - WOPRAI
[ Wed, May 31st 2023
] - WOPRAI
[ Wed, May 31st 2023
] - WOPRAI
[ Wed, May 31st 2023
] - WOPRAI
[ Wed, May 31st 2023
] - WOPRAI
[ Wed, May 31st 2023
] - WOPRAI
[ Wed, May 31st 2023
] - WOPRAI
[ Wed, May 31st 2023
] - WOPRAI
[ Wed, May 31st 2023
] - WOPRAI
[ Wed, May 31st 2023
] - WOPRAI
[ Wed, May 31st 2023
] - WOPRAI
[ Wed, May 31st 2023
] - WOPRAI
[ Wed, May 31st 2023
] - WOPRAI
[ Wed, May 31st 2023
] - WOPRAI
[ Wed, May 31st 2023
] - WOPRAI
[ Wed, May 31st 2023
] - WOPRAI
Christopher Raymond Upgraded (AKBA) to Buy and Increased Target to $4 on, May 31st, 2023
Christopher Raymond of Piper Sandler, Upgraded "Akebia Therapeutics, Inc." (AKBA) to Buy and Increased Target from $2 to $4 on, May 31st, 2023.
Christopher has made no other calls on AKBA in the last 4 months.
There is 1 other peer that has a rating on AKBA. Out of the 1 peers that are also analyzing AKBA, all agrees with Christopher's Rating of Hold. Following is the relevant analyst calls for the last 4 months
- Ed Arce of "HC Wainwright & Co." Reiterated at Hold and Held Target at $2 on, Tuesday, May 30th, 2023
